ALB and COVID-19: Advances in nanomedicine have enabled effective delivery of chemotherapeutics and RNA drugs, leading to the approval and clinical application of several nanoparticle-formulated products including DOXIL® (doxorubicin in liposome), Abraxane® (albumin-bound paclitaxel), Onivyde® (irinotecan in liposome), OnpattroTM (siRNAs in lipid nanoparticles) and most recently several mRNA-based COVID-19 vaccines 21-23.